Product Information
| Common Name |
Favipiravir |
| CAS Number |
259793-96-9 |
| Density |
1.6±0.1 g/cm3 |
| Molecular Formula |
C5H4FN3O2 |
| MSDS |
N/A |
| Molecular Weight |
157.103 |
| Boiling Point |
552.6±50.0 °C at 760 mmHg |
| Melting Point |
N/A |
| Flash Point |
288.0±30.1 °C |
| Exact Mass |
157.028748 |
| PSA |
88.84000 |
| Exact Mass |
157.028748 |
| PSA |
88.84000 |
| LogP |
0.78 |
| Vapour Pressure |
0.0±1.5 mmHg at 25°C |
| Index of Refraction |
1.600 |
| HS Code |
2934999090 |
Description:
Recommendation time: and Chinese patent medicine have been found to have a number of marketed drugs that are resistant in February 4th, Sun Yanrong, deputy director of the Biotechnology Center of the Ministry of science and technology, told the news conference of the national health and Health Committee.
Expert evaluation: on February 15, at the press conference of the joint prevention and control mechanism of the State Council, Zhang Xinmin, director of the biological center of the Ministry of science and technology, said that fabiravir is an overseas listed drug for the treatment of influenza. At present, clinical trials have been carried out in Shenzhen, with more than 70 patients in the group, including the control group, initially showing a more obvious effect and a lower adverse reaction. On the 3rd to 4th day after treatment, the negative rate of viral nucleic acid in the treatment group was significantly higher than that in the control group.
Application:
Favipiravir, also known as T705, or Avigan, is a selective inhibitor of viral RNA-dependent RNA polymerase with activity against many RNA viruses, influenza viruses, West Nile virus, yellow fever virus, foot-and-mouth disease virus as well as other flaviviruses, arenaviruses, bunyaviruses and alphaviruses. Activity against enteroviruses and Rift Valley fever virus has also been demonstrated. The mechanism of its actions is thought to be related to the selective inhibition of viral RNA-dependent RNA polymerase. Favipiravir does not inhibit RNA or DNA synthesis in mammalian cells and is not toxic to them. In 2014, favipiravir was approved in Japan for stockpiling against influenza pandemics.
Your message must be between 20-3,000 characters!
